Published on : Jun 12, 2018
Albany, New York, June 12, 2018: Medical institutions and pharmaceutical companies are akin on developing niche products that accelerate schizophrenia therapeutics pertaining to cognitive symptoms. Frontier Pharma, a leading investor in pharmaceutical companies has recently diverted its resources towards innovative drug discovery in schizophrenia. To understand the implications of novel developments in schizophrenia therapeutics for cognitive symptoms, Market Research Hub (MRH) has recently added a new research study titled, ‘Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms’, to its database.
MIN-101 Expected to Render New Methodology in Cognitive Schizophrenia Therapeutics
Owing to limited research and development in schizophrenia therapeutics, drug availability is considerably low. There are a number of vaccines and cell therapies that are in various stages of clinical research.
According to a recent report, scientists in Virginia Commonwealth University are carrying out research trials to test the efficacy of HDAC inhibitors as a potent drug to correct cognitive functions in schizophrenia patients. Additionally, pharmaceutical companies are also carrying out significant research activities towards cognitive schizophrenia therapeutics development. Minerva Neurosciences, Inc. is carrying out a scientific trial on 500 schizophrenia patients to test the potency of MIN-101 to treat adult schizophrenia patients. The final research reports of the trial now in phase 3, are expected to be presented in 2020.
Further, to accelerate innovations in cognitive schizophrenia therapeutics, Vanderbuilt University and leading pharmaceutical company, Lundbeck have entered into a collaboration. According to this mutual agreement, the latter will have an access to all the compounds developed by the university related to schizophrenia, and thereby invest in drug development and trial processes centered on cognitive schizophrenia therapeutics.
Key Components: Frontier Pharma Schizophrenia First-in-Class Pipeline
Exhaustive research components encapsulated in the report presents the readers vital information about drug development of first-in-class pipeline supported by Frontier Pharma. These innovative mechanisms to coin relevant drugs in cognitive symptoms of schizophrenia has caused a thrust in schizophrenia first-in-class pipeline therapeutics. Based on first-in class pipeline the schizophrenia therapeutics market is stratified as therapeutics development under therapeutics development, schizophrenia first-in-class pipeline is classified as stage of development, molecule type, and molecule target. Based on the perspectives presented in the report, readers can comprehend the growth of these components in schizophrenia first-in-class pipeline therapeutics undertaken by Frontier Pharma.
In-depth summary of research components presented in the report highlight key insights on the ongoing developments in Frontier Pharma schizophrenia drug development of first-in-class pipeline. Market players can gain vital cues from these insights to gauge the recent developments and subsequently administer the same in their research trial plans to augment first-in-class drug development for schizophrenia.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1821759
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org